| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| sarilumab | high affinity immunoglobulin gamma fc receptor i | biotech | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
NA | approved,investigational | unknown |
| sarilumab | high affinity immunoglobulin gamma fc receptor i | biotech | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Rheumatoid Arthritis[MeSHID:D001172] Disease[MeSHID:D004194] |
NA | approved,investigational | unknown |
| sarilumab | low affinity immunoglobulin gamma fc region receptor ii-a | biotech | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
NA | approved,investigational | unknown |
| sarilumab | low affinity immunoglobulin gamma fc region receptor ii-a | biotech | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Rheumatoid Arthritis[MeSHID:D001172] Disease[MeSHID:D004194] |
NA | approved,investigational | unknown |
| sarilumab | low affinity immunoglobulin gamma fc region receptor ii-b | biotech | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Rheumatoid Arthritis[MeSHID:D001172] Disease[MeSHID:D004194] |
NA | approved,investigational | unknown |
| sarilumab | low affinity immunoglobulin gamma fc region receptor ii-b | biotech | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
NA | approved,investigational | unknown |
| sarilumab | low affinity immunoglobulin gamma fc region receptor iii-a | biotech | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Rheumatoid Arthritis[MeSHID:D001172] Disease[MeSHID:D004194] |
NA | approved,investigational | unknown |
| sarilumab | low affinity immunoglobulin gamma fc region receptor iii-a | biotech | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
NA | approved,investigational | unknown |
| sarilumab | low affinity immunoglobulin gamma fc region receptor iii-b | biotech | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Rheumatoid Arthritis[MeSHID:D001172] Disease[MeSHID:D004194] |
NA | approved,investigational | unknown |
| sarilumab | low affinity immunoglobulin gamma fc region receptor iii-b | biotech | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
NA | approved,investigational | unknown |
| sarilumab | interleukin-6 receptor subunit alpha | biotech | NA | drugbank , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Rheumatoid Arthritis[MeSHID:D001172] |
56.58 | approved,investigational | antagonist,antibody |
| sarilumab | interleukin-6 receptor subunit alpha | biotech | NA | drugbank , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Coronavirus Infections[MeSHID:D018352] Rheumatoid Arthritis[MeSHID:D001172] Disease[MeSHID:D004194] |
56.58 | approved,investigational | antagonist,antibody |
| click here to return to the previous page | ||||||||